LIFECORE BIOMEDICAL INC (LFCR) Stock Price & Overview

NASDAQ:LFCR • US5147661046

Current stock price

4.915 USD
0 (-0.1%)
Last:

The current stock price of LFCR is 4.915 USD. Today LFCR is down by -0.1%. In the past month the price increased by 17.42%. In the past year, price decreased by -22.88%.

LFCR Key Statistics

52-Week Range3.625 - 8.9799
Current LFCR stock price positioned within its 52-week range.
1-Month Range3.625 - 5.53
Current LFCR stock price positioned within its 1-month range.
Market Cap
184.214M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.07
Dividend Yield
N/A

LFCR Stock Performance

Today
-0.1%
1 Week
-5.38%
1 Month
+17.42%
3 Months
-42.66%
Longer-term
6 Months -27.43%
1 Year -22.88%
2 Years -23.36%
3 Years +15.76%
5 Years N/A
10 Years N/A

LFCR Stock Chart

LIFECORE BIOMEDICAL INC / LFCR Daily stock chart

LFCR Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to LFCR. When comparing the yearly performance of all stocks, LFCR is a bad performer in the overall market: 90.7% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

LFCR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LFCR. LFCR may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LFCR Earnings

On April 8, 2026 LFCR reported an EPS of -0.29 and a revenue of 31.11M. The company missed EPS expectations (-18.46% surprise) and beat revenue expectations (15.09% surprise).

Next Earnings DateAug 5, 2026
Last Earnings DateApr 8, 2026
PeriodQ1 / 2026
EPS Reported-$0.29
Revenue Reported31.11M
EPS Surprise -18.46%
Revenue Surprise 15.09%

LFCR Forecast & Estimates

11 analysts have analysed LFCR and the average price target is 6.63 USD. This implies a price increase of 34.89% is expected in the next year compared to the current price of 4.915.

For the next year, analysts expect an EPS growth of 28.52% and a revenue growth -4.2% for LFCR


Analysts
Analysts81.82
Price Target6.63 (34.89%)
EPS Next Y28.52%
Revenue Next Year-4.2%

LFCR Groups

Sector & Classification

LFCR Financial Highlights

Over the last trailing twelve months LFCR reported a non-GAAP Earnings per Share(EPS) of -1.07. The EPS increased by 20.48% compared to the year before.


Income Statements
Revenue(TTM)174.18M
Net Income(TTM)-44.00M
Industry RankSector Rank
PM (TTM) N/A
ROA -18.71%
ROE -119.61%
Debt/Equity 3.67
Chartmill High Growth Momentum
EPS Q2Q%40.82%
Sales Q2Q%25.93%
EPS 1Y (TTM)20.48%
Revenue 1Y (TTM)33.67%

LFCR Ownership

Ownership
Inst Owners76.22%
Shares37.48M
Float36.68M
Ins Owners1.86%
Short Float %7.07%
Short Ratio7.6

About LFCR

Company Profile

LFCR logo image Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Company Info

IPO: 1996-02-15

LIFECORE BIOMEDICAL INC

3515 Lyman Boulevard

Chaska MINNESOTA US

Employees: 406

LFCR Company Website

LFCR Investor Relations

Phone: 18009279800

LIFECORE BIOMEDICAL INC / LFCR FAQ

What does LFCR do?

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. The company is headquartered in Chaska, Minnesota and currently employs 406 full-time employees. The firm designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The firm offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. The company is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The firm uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.


Can you provide the latest stock price for LIFECORE BIOMEDICAL INC?

The current stock price of LFCR is 4.915 USD. The price decreased by -0.1% in the last trading session.


Does LFCR stock pay dividends?

LFCR does not pay a dividend.


How is the ChartMill rating for LIFECORE BIOMEDICAL INC?

LFCR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


When does LIFECORE BIOMEDICAL INC (LFCR) report earnings?

LIFECORE BIOMEDICAL INC (LFCR) will report earnings on 2026-08-05.


What is the outstanding short interest for LIFECORE BIOMEDICAL INC?

The outstanding short interest for LIFECORE BIOMEDICAL INC (LFCR) is 7.07% of its float.